Advertisement

Bladder Cancer Medications

Here's a list of the approved drugs to treat bladder cancer. Click on any of the medications for more info on indications, dosing and side effects.


Quick Filter

*generic version available

E experimental

DRUG Chemotherapy
GENERIC NAME Multiple
DRUG INDICATION

Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, click here.

DRUG Jelmyto
GENERIC NAME mytomycin
DRUG INDICATION

Jelmyto is an alkylating drug approved for the treatment of low-grade urothelial cancer in the upper urinary tract.

DRUG Bavencio
GENERIC NAME avelumab
DRUG INDICATION

Bavencio is a checkpoint inhibitor approved for advanced or metastatic bladder (urothelial) cancer—both as maintenance therapy and for patients who progress on chemotherapy—metastatic Merkel cell carcinoma and advanced kidney cancer (renal cell carcinoma).

DRUG Imfinzi
GENERIC NAME durvalumab
DRUG INDICATION

Imfinzi is a checkpoint inhiibtor approved for advanced or metastatic bladder (urothelial) cancer, inoperable non-small-cell lung cancer and extensive-stage small cell lung cancer.

DRUG Keytruda
GENERIC NAME pembrolizumab
DRUG INDICATION

Keytruda is a PD-1 checkpoint inhibitor approved for inoperable or metastatic melanoma, adjuvant treatment of melanoma after surgery, non-small-cell lung cancer, bladder (urothelial) cancer, head and neck cancer, esophageal cancer, liver cancer, kidney cancer, stomach cancer, classic Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, Merkel cell carcinoma, cutaneous squamous cell carcinoma and triple-negative breast cancer. It is also approved for all metastatic solid tumors with high microsatellite instability or mismatch repair deficiency mutations (MSI-H/dMMR) or high tumor mutation burden. 

DRUG Opdivo
GENERIC NAME nivolumab
DRUG INDICATION

Opdivo is a checkpoint inhibitor approved for inoperable or metastatic melanoma, metastatic or recurrent non-small-cell lung cancer, advanced kidney cancer, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, advanced or metastatic bladder (urothelial) cancer, liver cancer, advanced stomach and esophageal cancer, malignant pleural mesothelioma and colorectal cancer with high microsatellite instability or mismatch repair deficiency genetic mutations. 

DRUG Tecentriq
GENERIC NAME atezolizumab
DRUG INDICATION

Tecentriq is a checkpoint inhibitor approved for the treatment of advanced or metastatic bladder (urothelial) cancer, metastatic non-small-cell lung cancer, extensive-stage small-cell lung cancer, triple-negative breast cancer, metastatic liver cancer and inoperable or metastatic melanoma.

DRUG TICE
GENERIC NAME Bacillus Calmette-Guerin
DRUG INDICATION

TICE is BCG bacteria approved to treat early-stage bladder (urothelial) cancer and prevent recurrence.

DRUG Balversa
GENERIC NAME erdafitinib
DRUG INDICATION

Balversa is a kinase inhibitor approved for previously treated locally advanced or metastatic bladder cancer (urothelial carcinoma) that carries FGFR genetic mutations.

DRUG Padcev
GENERIC NAME enfortumab vedotin-ejfv
DRUG INDICATION

Padcev is an antibody-drug conjugate approved for adults with locally advanced or metastatic bladder cancer and other urothelial cancers who previously received PD-1 or PD-L1 checkpoint inhibitors and platinum-based chemotherapy.

DRUG Rozlytrek
GENERIC NAME entrectinib
DRUG INDICATION

Rozlytrek is approved for the treatment of solid tumors anywhere in the body that have NTRK gene fusions and for ROS1-positive non-small-cell lung cancer.

DRUG Trodelvy
GENERIC NAME sacituzumab govitecan
DRUG INDICATION

Trodelvy is an antibody-drug conjugate approved for the treatment of metastatic triple-negative breast cancer and advanced bladder (urothelial) cancer.

DRUG Vitrakvi
GENERIC NAME larotrectinib
DRUG INDICATION

Vitrakvi is a TRK inhibitor that works against cancers anywhere in the body with NTRK gene fusions.


Advertisement